Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates
Sign Up to like & getrecommendations! Published in 2017 at "Iranian Biomedical Journal"
DOI: 10.18869/acadpub.ibj.21.4.270
Abstract: Background: Reduction/alkylation is one of the leading strategies for the development of antibody drug conjugates (ADCs). Precise control of the reduction process would not only yield a defined number of free thiols per antibody but… read more here.
Keywords: reduction; antibody; development antibody; antibody reduction ... See more keywords
Development of Antibody-Drug Conjugates: Future Perspective towards Solid Tumor Treatment.
Sign Up to like & getrecommendations! Published in 2022 at "Anti-cancer agents in medicinal chemistry"
DOI: 10.2174/1871520623666221031105432
Abstract: Antibody-Drug Conjugates (ADCs) are basically a targeted drug delivery system where tumour antigen-specific antibodies are used for targeting particular tumor cells and cytotoxic materials are conjugated with it by a linker molecule. Till now, twelve… read more here.
Keywords: tumor; drug conjugates; development antibody; drug ... See more keywords
Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders—An Update
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12071868
Abstract: Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are molecular imaging strategies that typically use radioactively labeled ligands to selectively visualize molecular targets. The nanomolar sensitivity of PET and SPECT combined with the… read more here.
Keywords: pet spect; pet; immuno pet; development antibody ... See more keywords